Amgen, Bind Partner To Develop Targeted Nanomedicine For Cancer
This article was originally published in The Pink Sheet Daily
Amgen will develop a targeted cancer medicine using a novel Accurin from Bind’s nanomedicine platform and one of its proprietary kinase inhibitors; the deal represents the first major partnership applying a nanomedicine technology to a molecularly targeted drug.
You may also be interested in...
The nanomedicine developer said it expects to have results from two Phase II trials before the end of the year potentially validating its technology platform during its first year-end sales and earnings call since completing an IPO in September.
Researchers have devised a tiny synthetic peptide that signals macrophages scavenging for foreign invaders in the body to ignore it and move on. The molecule can be attached to imaging agents, drugs, and biologics, increasing their uptake by shielding them from attack by the immune system.
Strong preclinical data for BIND-014, docetaxel-carrying particles engineered using BIND’s Accurin platform, translated into positive results against tumors not usually vulnerable to the cancer drug, the company reported at a late-breaker poster session of the American Association for Cancer Research annual meeting.